Peptide-Guided Drug Carriers That Cross the Blood-Brain Barrier to Target Brain Tumors

Comprehensive review of the literature on peptide-directed liposomal delivery systems for glioblastoma. The authors describe internalization mechanisms of specific glioblastoma-homing and BBB-penetrating peptides, review preclinical studies of liposomes functionalized with these peptides, and assess the current state and challenges of translating these approaches to clinical use.

Glioblastoma is the most lethal brain cancer, with a median survival of about 15 months. The BBB blocks most chemotherapy drugs from reaching the tumor, and even drugs that cross it often don't penetrate deeply into the tumor mass. Peptide-guided liposomes offer a potentially elegant solution: targeted, deep-penetrating drug delivery that could fundamentally change treatment outcomes for this devastating cancer.

Glioblastoma drug delivery is one of the most challenging problems in oncology. The convergence of peptide targeting technology with liposomal drug delivery represents a sophisticated approach that could overcome the fundamental access problem. If these nanosystems can be scaled up for manufacturing and validated in clinical trials, they could transform treatment not just for glioblastoma but for other brain diseases where the BBB blocks drug access.

All evidence is preclinical — no peptide-functionalized liposome systems have reached clinical trials for glioblastoma. Manufacturing complexity and reproducibility are major unsolved challenges. The review acknowledges that antibody-based targeting approaches are more clinically advanced competitors. Animal models of glioblastoma have limited predictive value for human outcomes.